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The challenge of studying complex protein networks in whole animals has driven the development of
new methods for manipulating protein function with spatial and temporal precision. A novel combination
of chemical and genetic protein regulation (Rodriguez and Wolfgang, in this issue of Chemistry & Biology)
achieves levels of control that will revolutionize the study of protein function.Identifying the function of a protein has
often relied on characterizing the impact
of naturally occurring or directed muta-
tions in the gene encoding that protein.
Protein functions were first elucidated
in microorganisms through the use of
temperature-sensitive alleles, mutations,
and deletions. In whole organisms, devel-
opmental biologists successfully de-
scribed a variety of complex protein
networks by designing ways to perturb
specific proteins in model organisms
and characterizing the resulting pheno-
types. The past 20 years have seen the
advent of homologous recombination
techniques in mice that enable protein
regulation through mutations, transcrip-
tional control, and RNAi (Thomas and
Capecchi, 1990). However, many of
these technical advances have serious
drawbacks. Attenuated gene expression,
gene knockouts, and mutations in mam-
mals frequently have lethal or detrimental
outcomes during early development that
prevent exploration of protein function
on whole animal physiology and at later
stages. Although RNAi has proven to be
a powerful knockdown technique, de-
signing functional RNAi probes can beproblematic, because it is difficult to
predict if a given sequence will attenuate
mRNA levels. Further, changes in mRNA
levels do not always produce a corre-
sponding change in protein levels. De-
spite these challenges, it is critical to
develop approaches that study the func-
tion of proteins in whole animals because
complicated and overlapping factors
such as secreted factors, cell-cell interac-
tions, and metabolic state most certainly
impact protein function but are impos-
sible to replicate in less complex systems.
Therefore, the future of functional protein
studies in whole organisms lies in devel-
oping sophisticated tools that reversibly
regulate proteins in a specific time and
place.
Our understanding of complex biolog-
ical networks would particularly benefit
from improved capabilities in controlling
the levels of any given protein with fine-
tuned precision. For example, studies of
lipid metabolism have been especially
challenging because there are often
many similar proteins (as defined by
enzymatic properties) in the vertebrate
genome that can act in concert with func-
tionally-related lipid-modifying proteins.Elucidating the function of these proteins
would be facilitated by designing experi-
ments that discretely control expression
of a protein. To this end, small molecule-
mediated protein regulation has been
the most successful approach to tempo-
rally regulate proteins due to its broad
applicability to almost any protein of
study, its specificity in targeting, and its
reversibility. The basic principle of this
approach is to fuse inherently unstable
protein domains to a protein of interest,
thereby conferring instability to the entire
fusionconstruct. Introducingabiologically
inert small molecule that binds specifically
to the unstable protein domain in the
fusion construct subsequently stabilizes
the fusion protein in a dose-dependent
manner, thereby effectively activating
the protein of interest. Reversal of this
process is achieved by removing the
small molecule. Several groups have
spent the better part of a decade modi-
fying and perfecting a small protein
domain of FK506 binding protein 12
(FKBP12) that can convey instability to
any protein to which it is fused (Stankunas
et al., 2003; Yang et al., 2000). Improve-
ments in high throughput structure-basedª2012 Elsevier Ltd All rights reserved 311
Figure 1. Spatial and Temporal Control of Proteins
CFP, mCherry, and YFP are used to trace incorporation, recombination, and activation of the construct,
respectively. The use of fluorescent markers allows each of these steps to be monitored in real time. (1)
CFP is used to indicate the incorporation of the construct into a mouse. YFP and mCherry are not
translated. (2) Tissue-specific CRE induces homologous recombination that removes the CFP signal
and activates the mCherry signal in the tissue of interest (represented by the oval). The unstable degrada-
tion domain (DD, in gray) causes the degradation of the DD-YFP-protein of interest (POI, in black)
construct as indicated by the absence of YFP signal. (3) Similar to line 2, CRE removes the CFP signal
and activates mCherry. The DD is stabilized by binding to a small, biologically-inert molecule (sm, in
purple), penultimately resulting in a stabilized fusion construct indicated by a YFP signal.
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molecule screening enabled predictions
of how modifications of FKBP12 convey
significantly higher affinity to a variety of
stabilizing ligands, including the highly
specific and biologically inert small mole-
cule Shield-1.
In this issue, Rodriguez and Wolfgang
(2012) have taken advantage of the
FKBP12/Shield-1 regulatory mechanism
to design a tractable method to control
malonyl-CoA decarboxylase (MLYCD)
expression. The authors cleverly employ
three fluorescent proteins to trace the
incorporation and activation of a construct
(Figure 1). First, MLYCD was fused to the
previously published YFP-tagged version
of the mutated degradation domain of
FKBP12, called FKBP, so that the stable
fusion protein can be observed via YFP
fluorescence in real time (Banaszynski
et al., 2006). They verified that the
N-terminal fusion to MLYCD does not
affect the enzymatic function of stabilized
MLYCD. Second, because the YFP
signal is only produced in the presence
of the stabilizing small molecule Shield-1,
the authors incorporatedmCherry into the
fusion construct through a 2A peptide
linker, which allows the production of
two proteins from a single mRNA at a
1:1 stoichiometric ratio (Szymczak et al.,
2004). In doing so, the expression of
this construct can be verified by analyzing
mCherry fluorescence even in the
absence of Shield-1. Finally, the authors
incorporated CFP, flanked by loxP sites,
50 of the YFP-FKBP-MLYCD-2A-mCherry
so that integration of the construct into312 Chemistry & Biology 19, March 23, 2012cells and tissues can be monitored. Incor-
porating the CRE/Lox approach creates
a ‘‘dual inducible system’’ that allows
both temporal (small molecule-mediated
inhibition) and spatial (CRE-mediated
tissue expression) control of the overex-
pression of a protein of interest. The
authors’ elegant use of fluorescent pro-
teins to trace the various key steps in
this process (e.g., integration, recombina-
tion, and protein stabilization) sets it apart
from previous studies employing small
molecule-mediated inhibition.
Rodriguez and Wolfgang (2012) vali-
date a novel technique that has several
advantages over the currently favored
approach for temporal control over over-
expressed proteins inmice, the rtTA tetra-
cycline system (Gossen et al., 1995).
These advantages include the following.
(1) Typically only one transgenic mouse
line needs to be created as opposed to
multiple lines because of the large number
of tissue-specific CRE lines as compared
to rtTA lines. (2) Not all tissues are acces-
sible to doxycycline (e.g., brain, testis),
the antibiotic used to induce expression
(Beard et al., 2006). (3) Using the
FKBP12 fusion results in protein degrada-
tion when Shield-1 is withdrawn, whereas
removal of doxycycline only shuts down
transcription, leaving existing proteins
intact. This is not a problem for proteins
with a short half-life but can be an issue
for more stable proteins. (4) The use of
the viral 2A sequence allows for real-
time visual identification of transgene-ex-
pressing cells irrespective of the presence
of Shield-1. For the rtTA approach, thereª2012 Elsevier Ltd All rights reservedis no secondary marker to visually confirm
recombination in the absence of doxycy-
cline. (5) mCherry expression can serve
as a lineage marker for studies in which
Shield-1-regulated protein expression
could alter cell fate.
Rodriguez and Wolfgang (2012) have
pieced together cutting-edge aspects of
smallmolecule-mediatedchemical regula-
tion and mouse recombinant genetics to
generate a technique that is broadly appli-
cable to any protein that is unchanged
by a fusion to a small protein domain.
Importantly, the authors carefully instruct
how their approach is broadly applicable
to many genes and proteins, not just to
MLYCD. In their proof of principle article,
the authors successfully demonstrate the
most exciting possibility of their targeted
genetic-chemical technique: rapidly and
reversibly regulating theactivityofaprotein
in a tissue-specific and temporal manner.
Using their favorite protein as an example,
they are able to control the stability of
MLYCD in the skeletal muscle of mice.
However, they have kept us in suspense
as to the physiological effect of this induc-
ible MLYCD tissue-specific activation.
Rodriguez and Wolfgang (2012) have
succeeded in whetting our appetites for
future experiments that will surely capi-
talize on this technique. The ability to
regulate proteins in such a finely-tuned
manner will likely open up a world of new
possibilities for future studies.
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